Editorial
|
|
|
|
|
Protecting public health from big pharma's greed
|
|
|
|
Marketing Authorisations
|
|
|
|
|
A "mab" for hypercholesterolaemia: no evidence of benefits
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Another cholesterol-lowering "mab" with no evidence of efficacy
|
|
|
|
|
|
|
|
|
|
|
|
An anti-generic strategy that creates confusion
|
|
|
|
|
|
|
|
|
|
Yet another cancer drug authorised despite incomplete evaluation
|
|
|
|
Adverse Effects
|
|
|
|
|
Consistent data
|
|
|
|
|
|
|
|
|
|
|
|
Fluoroquinolones, statins, steroids
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reviews
|
|
|
|
|
Attention to detail makes supplementation more tolerable
|
|
|
|
|
|
|
|
Outlook
|
|
|
|
|
Alternatives to patent-based innovation and sponsored CME are needed
|
|
|
|
|
|
|
|
|
|